Results 11 to 20 of about 10,308 (152)
Imatinib mesylate in chordoma [PDF]
Cancer, 2004 AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Casali PG +17 more
openaire +2 more sources
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source
Uveitis – A side effect of imatinib mesylate
Indian Journal of Ophthalmology. Case Reports, 2023 Imatinib mesylate, a BCR-ABL tyrosine kinase inhibitor, is widely used in the management of chronic myeloid leukemia (CML). Although there are a few studies documenting ocular side effects of imatinib, there have been no reports of uveitis caused by ...
BN Kalpana +3 more
doaj +1 more source
Journal of Medical Case Reports, 2011 Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid +11 more
doaj +1 more source
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
BMC Cancer, 2010 Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming +4 more
doaj +1 more source
Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
Iraqi Journal of Hematology, 2020 BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj +1 more source
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
Turkish Journal of Hematology, 2015 Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino +7 more
doaj +1 more source
Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
Journal of the Scientific Society, 2023 Imatinib mesylate is an oral tyrosine kinase inhibitor used chiefly to treat chronic myeloid leukemia. In the literature, hypopigmentation is a commonly reported side effect of imatinib therapy; however, the cases of melasma-like hyperpigmentation due to
Shreya Agrawal +3 more
doaj +1 more source
Veterinární Medicína, 2019 A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem.
Joong Hyun Song +6 more
doaj +1 more source